Quantitation of thrombin-activatable fibrinolysis inhibitor in human plasma by isotope dilution mass spectrometry.

CBP2 Mass spectrometry Pro-carboxypeptidase U TAFI Thrombin-activatable fibrinolysis inhibitor

Journal

Analytical biochemistry
ISSN: 1096-0309
Titre abrégé: Anal Biochem
Pays: United States
ID NLM: 0370535

Informations de publication

Date de publication:
01 02 2022
Historique:
received: 11 06 2021
revised: 07 10 2021
accepted: 08 10 2021
pubmed: 14 10 2021
medline: 2 2 2022
entrez: 13 10 2021
Statut: ppublish

Résumé

Measurement of Thrombin-activatable fibrinolysis inhibitor (TAFI) in human plasma is dependent on reproducible assays. To date, standards for measuring TAFI are frequently calibrated relative to pooled normal human plasma and arbitrarily assigned a potency of 100% TAFI, despite variation in TAFI concentrations between plasma pools. Alternatively, TAFI calibrators can be assigned a value in SI units but the approach used for value assignment is not consistent and furthermore, if purified TAFI is used to determine TAFI concentration in plasma, may be adversely affected by matrix effects. A TAFI plasma standard in mass units with traceability to the SI unit of mass is desirable. We report here the establishment of a quantitative mass spectrometry method for TAFI in plasma. Traceability is obtained by reference to calibrators that consist of blank plasma spiked with a defined amount of purified TAFI, value assigned by amino acid analysis. The calibrators are run alongside the samples, using the same preparation steps and conditions; an acetonitrile assisted tryptic digestion and multi-dimensional liquid chromatography (LC) separation followed by MRM-MS analysis. We measured the TAFI quantitatively in human plasma with reproducibility, reliability and precision, and demonstrated the applicability of this approach for value assigning a common reference standard.

Identifiants

pubmed: 34644544
pii: S0003-2697(21)00314-6
doi: 10.1016/j.ab.2021.114413
pii:
doi:

Substances chimiques

Thrombin EC 3.4.21.5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114413

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Jun X Wheeler (JX)

National Institute for Biological Standards and Control, South Mimms, Potters Bar, EN6 3QG, UK.

Craig Thelwell (C)

National Institute for Biological Standards and Control, South Mimms, Potters Bar, EN6 3QG, UK.

Peter Rigsby (P)

National Institute for Biological Standards and Control, South Mimms, Potters Bar, EN6 3QG, UK.

Gail Whiting (G)

National Institute for Biological Standards and Control, South Mimms, Potters Bar, EN6 3QG, UK. Electronic address: gail.whiting@nibsc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH